How to dispose of the body

Abstract

To provide a method for treating a dead body, which injects a body fluid leakage-preventing agent stored in a device such as a dead body treatment device into a body cavity of a dead body, injects a deodorant exhibiting deodorant performance into a body cavity without mixed with the body fluid leakage-preventing agent.SOLUTION: An injector 10 storing a body fluid leakage-preventing agent 2 is prepared, the body fluid leakage-preventing agent 2 is extruded from the injector 10 and is injected toward a body cavity of a dead body S, and thereby leakage of body fluid from the body cavity is prevented. Before the body fluid leakage-preventing agent 2 is injected into the body cavity, a deodorant 3 is injected into the body cavity. The stench can be suppressed by the deodorant, and the deodorant 3 in addition to the body fluid can be prevented from being leaked from the body cavity.SELECTED DRAWING: Figure 2

Description

[Technical Field]

[0001] The present invention relates to a corpse treatment method using a corpse treatment device used on a deceased person, and more particularly to a corpse treatment method that suppresses leakage of internal substances from the body cavity of the corpse. [Background technology]

[0002] Generally, when a human or animal dies, the muscles corresponding to each body cavity relax, causing internal substances such as gastric juice, pulmonary fluid, ascites, and excrement to leak out of the body through each cavity of the corpse. This leakage of internal substances from the corpse is unhygienic and can have a negative impact on subsequent work such as transporting the corpse.

[0003] To address this, it is commonly known to prevent leakage of bodily fluids by sealing the holes in the corpse using a loader or the like as disclosed in Patent Document 1. Patent Document 1 describes a method for injecting a bodily fluid leakage prevention agent into the body cavity of a corpse using an instrument such as a loader, in which an injector filled with the bodily fluid leakage prevention agent is connected to an insertion tube, and the insertion tube is then inserted into the nostril or oral cavity, and the bodily fluid leakage prevention agent is pushed out of the injector, thereby injecting the bodily fluid leakage prevention agent into the throat via the insertion tube.

[0004] The corpse treatment method of Patent Document 1 has been put into practical use as a method that can reliably prevent leakage of body fluids from the throat, but in recent years, there has been a demand for further improvement in performance. In particular, there has been a growing demand for deodorizing the foul odor of the corpse when treating the corpse.

[0005] To address this issue, for example, Patent Document 1 discloses that the jelly-like body fluid leakage prevention agent filled in the loading device may further contain additives such as a deodorant.

[0006] Furthermore, Patent Document 2 discloses that an ionic polysaccharide such as κ-carrageenan or xanthan gum is mixed with a jelly-like body fluid leakage prevention agent such as that disclosed in Patent Document 1 in order to enhance deodorizing properties. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] Japanese Patent Application Laid-Open No. 2002-275001 [Patent Document 2] Patent No. 6763100 Summary of the Invention [Problem to be solved by the invention]

[0008] However, although Patent Document 1 discloses that the body fluid leakage prevention agent may further contain additives such as a deodorant, no specific additive has been found that can exhibit deodorizing performance while maintaining the benefits of a jelly-like body fluid leakage prevention agent.

[0009] Furthermore, in Patent Document 2, the deodorizing function is improved by adding an ionic polysaccharide to the body fluid leakage prevention agent, but the amount of ionic polysaccharide added to and mixed with the body fluid leakage prevention agent must be limited to an amount that does not interfere with the function of the body fluid leakage prevention agent, which poses the problem of having to limit the amount of ionic polysaccharide added to the body fluid leakage prevention agent.

[0010] The present invention has been made in consideration of the above points, and its object is to provide a method for treating a corpse in which a body fluid leakage prevention agent contained in an instrument such as a body treatment device is injected into the body cavity of a corpse, and which can inject the agent into the body cavity without mixing a deodorant that exhibits deodorizing performance into the body fluid leakage prevention agent. [Means for solving the problem]

[0011] In order to achieve the above object, the present invention is characterized in that a deodorant is injected into a body cavity without being mixed with a body fluid leakage prevention agent, and then the body fluid leakage prevention agent is injected into the body cavity.

[0012] Specifically, the first invention is a method for treating a corpse in which a syringe containing a bodily fluid leakage prevention agent is prepared, and the agent is pushed out of the syringe and injected into the body cavity of the corpse to prevent leakage of bodily fluids from the body cavity, and is characterized in that a deodorant is injected into the body cavity before the bodily fluid leakage prevention agent is injected into the body cavity.

[0013] In the first invention, the deodorant is injected into the body cavity without being mixed with the body fluid leakage prevention agent, so any type and appropriate amount of deodorant can be injected into the body cavity without interfering with the function of the body fluid leakage prevention agent. Furthermore, because the body fluid leakage prevention agent is injected after the deodorant is injected into the body cavity, the body fluid leakage prevention agent can prevent not only body fluids but also the deodorant from leaking out of the body cavity. Note that a body cavity is a part of the body from which body fluids may leak, such as the throat, anus, vagina, ears, wounds, bedsores, nutrient introduction holes, and drip holes.

[0014] The second invention is characterized in that, in the method for treating a corpse of the first invention, the deodorizer is an iodine-based deodorizer.

[0015] In the second invention, the deodorizer is an iodine-based deodorizer, so it can eliminate various odors of death, such as those caused by ammonia, gadaverine (amines), putrescine, butyric acid (butanoic acid), hydrogen sulfide, and methyl mercaptan.

[0016] The third invention is characterized in that, in the first or second invention, an insertion tube is prepared that is inserted into the nostrils or mouth of the corpse and that guides the bodily fluid leakage prevention agent in the syringe to the throat of the corpse, and the deodorant is injected into the throat before the bodily fluid leakage prevention agent in the syringe is injected into the throat of the corpse through the insertion tube.

[0017] In the third invention, the deodorant is injected into the throat before the bodily fluid leakage prevention agent in the injector passes through the insertion tube and is injected into the throat of the corpse, so the bodily fluid leakage prevention agent prevents the deodorant from leaking out of the throat. Also, because the deodorant is injected without being mixed with the bodily fluid leakage prevention agent, any type and appropriate amount of deodorant can be injected into the throat without interfering with the function of the bodily fluid leakage prevention agent.

[0018] The fourth invention is characterized in that, in the third invention, the bodily fluid leakage prevention agent is a jelly-like bodily fluid leakage prevention agent consisting of a large number of highly absorbent polymer powders dispersed in a jelly whose main component is alcohol.

[0019] In the fourth invention, the leakage prevention agent for bodily fluids is a jelly-like agent made of a jelly whose main component is alcohol and in which a large amount of highly water-absorbent polymer powder is dispersed, so that the agent in the syringe passes through the insertion tube and is smoothly injected toward the throat of the corpse. Furthermore, the jelly-like agent for bodily fluids prevents leakage of not only bodily fluids but also deodorant and corpse odors by absorbing moisture in the throat and expanding, thereby sealing the throat.

[0020] A fifth invention is characterized in that, in the third or fourth invention, the deodorant is injected toward the throat through the insertion tube inserted into the nostril or oral cavity.

[0021] In the fifth invention, the deodorant can be injected using an insertion tube inserted into the nostrils or oral cavity, so that the deodorant can be injected into the throat of the corpse simply and reliably.

[0022] The sixth invention is characterized in that, in the fifth invention, a container containing a deodorizer is prepared, the deodorizer in the container is poured into the insertion tube, and then the body fluid leakage prevention agent is poured into the insertion tube and injected into the throat area.

[0023] The sixth aspect of the present invention is excellent in workability because it eliminates the need to replace the insertion tube inserted into the nostril or oral cavity. In addition, since the deodorant flows through the insertion tube, the leakage prevention agent that passes after it can easily flow through the insertion tube.

[0024] The seventh invention is characterized in that, in the sixth invention, after connecting the container containing the deodorant to the insertion tube, the insertion tube is inserted into the nostril or oral cavity and the deodorant is injected into the throat through the insertion tube, and then after removing the container containing the deodorant from the insertion tube, the syringe containing the body fluid leakage prevention agent is connected to the insertion tube, and then the body fluid leakage prevention agent is injected into the throat through the insertion tube.

[0025] The seventh invention is easy to use because it eliminates the need to replace the insertion tube inserted into the nostril or oral cavity. In addition, since the deodorant flows through the insertion tube, the leakage prevention agent that passes after it can easily flow through the insertion tube.

[0026] The eighth invention is characterized in that, in the sixth invention, the insertion tube is a bifurcated insertion tube having a first connecting tube portion to which the injector can be connected and a second connecting tube portion to which the deodorant container can be connected, and after the injector and the deodorant container are connected to the first connecting tube portion and the second connecting tube portion of the bifurcated insertion tube, respectively, the bifurcated insertion tube is inserted into the nostrils and the oral cavity, and then the deodorant in the container is first injected toward the throat through the bifurcated insertion tube, and then the bodily fluid leakage prevention agent in the injector is injected toward the throat through the bifurcated insertion tube.

[0027] In the eighth invention, the injector and the container containing the deodorant are respectively connected to the bifurcated insertion tube, so there is no need to switch between the injector and the container containing the deodorant, and there is also no need to replace the bifurcated insertion tube, which is very convenient.

[0028] The ninth invention is characterized in that, in the sixth invention, the insertion tube is a bifurcated insertion tube having a first connecting tube portion to which the syringe can be connected and a second connecting tube portion to which the deodorant-containing container can be connected, and after the bifurcated insertion tube is inserted into the nostril or oral cavity, the syringe containing the bodily fluid leakage prevention agent is connected to the first connecting tube portion of the bifurcated insertion tube and the container containing the deodorant is connected to the second connecting tube portion of the insertion tube, and then the deodorant in the container is first injected toward the throat via the bifurcated insertion tube, and then the bodily fluid leakage prevention agent in the syringe is injected toward the throat via the insertion tube.

[0029] In the ninth invention, the syringe and the container containing the deodorant are connected to the bifurcated insertion tube, so there is no need to switch between the syringe and the container containing the deodorant, and there is no need to replace the bifurcated insertion tube, which is very convenient.

[0030] A tenth invention is characterized in that, in the sixth invention, the deodorant-containing container comprises a tubular member having a front connecting part connectable to the insertion tube at its front side and a rear connecting part connectable to the syringe at its rear side, and after connecting the front connecting part of the tubular member to the insertion tube and the rear connecting part to the syringe, the insertion tube is inserted into the nostril or oral cavity, and then the bodily fluid leakage prevention agent of the syringe is pushed toward the tubular member via the rear connecting part, thereby pushing the deodorant in the tubular member into the insertion tube via the front connecting part, and the bodily fluid leakage prevention agent is pushed into the insertion tube following the deodorant, and they are sequentially injected into the throat.

[0031] In the tenth invention, a deodorant-containing container having a tubular member containing a deodorant is connected between the insertion tube and the injector, so that when the deodorant in the tubular member is pushed into the insertion tube, the deodorant is pushed into the insertion tube, followed by the body fluid leakage prevention agent, and they are sequentially injected into the throat. This eliminates the need to change the insertion tube inserted into the nostrils or oral cavity, resulting in excellent operability. In addition, the flow of the deodorant inside the insertion tube makes it easier for the body fluid leakage prevention agent that passes later.

[0032] An eleventh invention is characterized in that, in the sixth invention, an intermediate cylinder is prepared which has a front connecting part connectable to the insertion tube at its front side, a rear connecting part connectable to the syringe at its rear side, and a spigot into which the deodorant container can be inserted at its midpoint, the front connecting part of the intermediate cylinder is connected to the insertion tube, the rear connecting part is connected to the syringe, and the insertion tube is then inserted into the nostril or the oral cavity, the deodorant container is then inserted into the spigot of the intermediate cylinder, the bodily fluid leakage prevention agent of the syringe is pushed toward the intermediate cylinder via the rear connecting part, the deodorant in the intermediate cylinder is pushed out into the insertion tube via the front connecting part, and the bodily fluid leakage prevention agent is pushed out into the insertion tube following the deodorant, and these are sequentially injected into the throat.

[0033] In the eleventh invention, by providing an intermediate cylinder, any container containing deodorant can be connected, and any amount or type of deodorant can be injected. Furthermore, there is no need to replace the insertion tube inserted into the nostril or oral cavity, making it easy to use. Furthermore, the flow of the deodorant through the insertion tube facilitates the flow of the body fluid leakage prevention agent that passes after it.

[0034] A twelfth invention is the sixth invention, characterized in that the deodorant-containing container is provided in the injector in a meltable or breakable manner, and after the deodorant-containing container is melted or broken, the bodily fluid leakage prevention agent in the injector is pushed out toward the insertion tube, and the deodorant in the deodorant-containing container is also pushed out.

[0035] In the twelfth invention, the container containing the deodorant provided in the syringe is meltable or breakable, so that after the syringe and the inserter are connected, when the bodily fluid leakage prevention agent in the syringe is pushed out, the deodorant is first guided into the insertion tube, and then the bodily fluid leakage prevention agent can be injected into the throat.

[0036] The thirteenth invention is characterized in that, in the sixth invention, the deodorant-containing container is attached to the tip of the insertion tube in a manner that allows it to melt or be broken, and the deodorant-containing container is pushed out into the throat while still containing the deodorant by a bodily fluid leakage prevention agent that is pushed from the inside of the injector through the insertion tube toward the throat, and then the deodorant-containing container is melted or broken in the throat.

[0037] In the thirteenth invention, a meltable or breakable container containing deodorant is attached to the tip of the insertion tube, so that the leakage prevention agent pushing out toward the throat pushes the container containing the deodorant toward the throat. At this time, the leakage prevention agent flows inside the insertion tube, so that the container containing the deodorant that passes after it can be easily injected into the throat.

[0038] The fourteenth invention is characterized in that in the sixth invention, the deodorant container is arranged in the insertion tube in a breakable manner, and the bodily fluid leakage prevention agent in the injector is sent to the insertion tube to break the deodorant container, thereby pushing the deodorant out of the insertion tube and into the throat, and subsequently the bodily fluid leakage prevention agent is also pushed out toward the throat.

[0039] In the fourteenth invention, when the leakage prevention agent in the syringe is sent to the insertion tube, the container containing the deodorant placed in the insertion tube breaks, forcing the deodorant out of the insertion tube and into the throat, making it easy to inject the deodorant and leakage prevention agent in sequence.

[0040] A fifteenth invention is characterized in that, in the fifth invention, the insertion tube comprises a first insertion tube through which the body fluid leakage prevention agent passes and a second insertion tube through which the deodorant passes, and after the second insertion tube is inserted into the nostril or oral cavity, the deodorant is injected into the throat through the second insertion tube, and then the first insertion tube is inserted into the nostril or oral cavity, and the body fluid leakage prevention agent is injected into the throat through the first insertion tube.

[0041] The fifteenth invention is provided with a first insertion tube through which the body fluid leakage prevention agent passes and a second insertion tube through which the deodorant passes, so that when using the syringe and deodorant, there is no need to swap the syringe and the container containing the deodorant with respect to the insertion tube, making the operation simple.

[0042] A sixteenth invention is characterized in that in the fifteenth invention, the outer diameter of the second insertion tube is smaller than the outer diameter of the first insertion tube.

[0043] In the sixteenth aspect of the present invention, the outer diameter of the second insertion tube is smaller than the outer diameter of the first insertion tube, so that the second insertion tube for the deodorant can be easily passed through the nostril.

[0044] The 17th invention is characterized in that, in the 15th or 16th invention, the second insertion tube is formed integrally with the first insertion tube and is inserted into the nostril or oral cavity together with the first insertion tube.

[0045] In the seventeenth aspect of the present invention, the first and second insertion tubes are provided integrally and are inserted into the nostril or oral cavity together, resulting in good work efficiency.

[0046] The 18th invention is characterized in that, in the 15th or 16th invention, the second insertion tube is provided separately from the first insertion tube and is inserted into the nostril or oral cavity separately from the first insertion tube.

[0047] In the eighteenth invention, the second insertion tube is separate from the first insertion tube and is inserted into the nostril or the oral cavity separately, so that the second insertion tube and the first insertion tube can be inserted into different nostrils, and the second insertion tube can be inserted to inject a deodorant, then pulled out, and then the first insertion tube can be inserted into the nostril to inject a body fluid leakage prevention agent. In this case, the second insertion tube may be made small in diameter or made of a soft material so that it can serve as a guide for inserting the first insertion tube.

[0048] The 19th invention is characterized in that, in any one of the first to fourth inventions, the deodorizer is a capsule contained in a dissolvable package or a tablet made of powder solidified to a predetermined size, and the capsule or tablet is inserted into the body cavity of the corpse, and then the body fluid leakage prevention agent in the injector is injected into the body cavity.

[0049] In the 19th invention, after a deodorant in the form of a capsule or tablet is inserted into the body cavity of the corpse, the bodily fluid leakage prevention agent in the syringe is injected into the body cavity, so that the deodorant can be inserted into the body cavity reliably, and the body cavity can be sealed with the bodily fluid leakage prevention agent injected later. [Effects of the Invention]

[0050] As explained above, according to the present invention, in a device such as a loader that is filled with a jelly-like body fluid leakage prevention agent and injected into the body cavity of a corpse, the odor of death can be prevented because the deodorant that exhibits deodorizing properties is injected into the body cavity without being mixed with the body fluid leakage prevention agent. Furthermore, because the body fluid leakage prevention agent is injected into the body cavity after the deodorant, the body fluid leakage prevention agent can prevent the deodorant from leaking out of the body cavity. [Brief explanation of the drawings]

[0051] [Figure 1] 1 is a schematic diagram showing a corpse treatment device used when carrying out a corpse treatment method according to embodiment 1 of the present invention. [Figure 2] FIG. 2 is a schematic diagram illustrating the state in which a deodorant and a bodily fluid leakage prevention agent according to the first embodiment of the present invention are being injected into a corpse using the corpse treatment apparatus of FIG. [Figure 3] 1 is a graph showing the deodorizing performance of the deodorizer according to embodiment 1 of the present invention against one of the malodor components of a corpse. [Figure 4] 10 is a graph showing the deodorizing performance of the deodorizer according to embodiment 1 of the present invention against another malodor component of a corpse. [Figure 5] 10 is a graph showing the deodorizing performance of the deodorizer according to embodiment 1 of the present invention against another malodor component of a corpse. [Figure 6] 10 is a graph showing the deodorizing performance of the deodorizer according to embodiment 1 of the present invention against another malodor component of a corpse. [Figure 7] 10 is a graph showing the deodorizing performance of the deodorizer according to embodiment 1 of the present invention against another malodor component of a corpse. [Figure 8] 10 is a schematic diagram showing a corpse treatment device used when carrying out a corpse treatment method according to a second embodiment of the present invention. FIG. [Figure 9] 10 is a schematic diagram showing a corpse treatment device used when carrying out a corpse treatment method according to a third embodiment of the present invention. FIG. [Figure 10] 10 is a schematic diagram showing a corpse treatment device used when carrying out a corpse treatment method according to a fourth embodiment of the present invention. FIG. [Figure 11] 10 is a schematic diagram showing a corpse treatment device used when carrying out a corpse treatment method according to embodiment 5 of the present invention. FIG. [Figure 12] 10 is a schematic diagram showing a corpse treatment device used when carrying out a corpse treatment method according to a sixth embodiment of the present invention. FIG. [Figure 13] FIG. 10 is a schematic diagram showing an example of a corpse treatment device used when carrying out a corpse treatment method according to embodiment 7 of the present invention. [Figure 14] FIG. 14 is a schematic diagram showing an example of a corpse treatment apparatus used when carrying out a corpse treatment method according to the eighth embodiment of the present invention. [Figure 15] FIG. 15 is a schematic diagram showing an example of a corpse treatment device used when carrying out a corpse treatment method according to embodiment 9 of the present invention. [Figure 16] FIG. 16 is a schematic diagram showing a corpse treatment apparatus used when carrying out a corpse treatment method according to embodiment 10 of the present invention. DETAILED DESCRIPTION OF THE INVENTION

[0052] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The following description of preferred embodiments is merely exemplary in nature and is not intended to limit the scope of the present invention, its applications, or uses.

[0053] (Embodiment 1) The corpse treatment apparatus according to the first embodiment of the present invention will be outlined with reference to the drawings. Fig. 1 is a schematic diagram showing the corpse treatment apparatus according to the first embodiment of the present invention. Fig. 2 is a schematic diagram illustrating the state in which a deodorant and a body fluid leakage prevention agent are injected into a corpse using the corpse treatment apparatus according to the first embodiment of the present invention. Figs. 3 to 7 are graphs showing the deodorizing performance of the deodorant used in the first embodiment of the present invention against various malodorous components in a corpse.

[0054] In the first embodiment, the present invention is applied to a case in which the insertion tube 20 of the corpse treatment device 1 (loader) is inserted into a nostril A, and a deodorant 3 in a deodorant-containing container 30 and a body fluid leakage prevention agent 2 in an injector 10 are injected into the throat B of a corpse S. FIG. 1 shows the corpse treatment device 1 having an injector 10 containing a body fluid leakage prevention agent 2 according to the first embodiment of the present invention, an insertion tube 20 inserted into a nostril A of a corpse S, and a deodorant-containing container 30. FIG. 2 shows a state of use in which the deodorant-containing container 30 is connected to the insertion tube 20 and the injector 10, and the deodorant 3 in the deodorant-containing container 30 and the body fluid leakage prevention agent 2 in the injector 10 are injected into the body cavity (throat B) of the corpse S through the same insertion tube 20. In FIG. 2, S represents the corpse, A represents the nostrils, B represents the throat, C represents the tongue, D represents the trachea, E represents the esophagus, F represents the cervical vertebrae, and G represents the oral cavity.

[0055] Next, the corpse treatment device 1 for injecting the deodorant 3 and the body fluid leakage prevention agent 2 into the throat B will be described with reference to FIGS.

[0056] As shown in Figure 1, the injector 10 is composed of a syringe 11 and a piston 12. The syringe 11 has a cylindrical container 13 filled with the body fluid leakage prevention agent 2, and a nozzle 14 protruding from the tip of the container 13. The nozzle 14 tapers gradually toward the tip and has two protrusions 15 on its outer periphery. A protective cap 16 is detachably attached to the tip of the protrusion 15.

[0057] The insertion tube 20 has a tube body 21 made of a soft and flexible synthetic resin material such as soft vinyl chloride, and the tube body 21 is designed to bend when inserted from the nostril A toward the throat B. A connecting tube 23 is provided at the rear end of the tube body 21, which can be connected to the nozzle 14 of the injector 10 and also to the deodorant container 30.

[0058] The tube main body 21 has a long, thin cylindrical shape like a hollow tube. This tube main body 21 has both flexibility that allows it to deform according to the internal shape from the nostril A to the throat B, and rigidity that prevents the internal passage of the tube main body 21 from collapsing when inserted into the nostril A.

[0059] An injection hole 22 communicating with the interior of the tube main body 21 is provided at the axial tip end of the tube main body 21. The injection hole 22 includes four side injection holes 22a and a tip injection hole 22b. Each injection hole 22 guides the deodorant 3 and the body fluid leakage prevention agent 2 injected from the injector 10 into the tube main body 21 into the throat B of the corpse S. A stopper 24 having a generally C-shape that protrudes radially outward and extends circumferentially is integrally formed with the connecting tube 23. The stopper 24 is positioned so that it will abut against the tip of the nose A1 when the injection holes 22 of the tube main body 21 reach the throat B. A circumferentially extending groove 25 is provided in the axial middle of the connecting tube 23. Two grooves 25 are formed circumferentially at a predetermined interval. The grooves 25 are adapted to engage with the protrusions 35 of the deodorant-filled tubular member 31. In FIG. 1, the deodorant 3 is partially omitted in order to clearly show the protruding portion 35.

[0060] The deodorant container 30 comprises a tubular member 31 containing the deodorant 3 therein. The tubular member 31 has a front connecting part 33 at the front that can be connected to the connecting tube part 23 of the insertion tube 20, and a rear connecting part 34 at the rear that can be connected to the nozzle 14 of the injector 10. The deodorant 3 is wrapped in a storage bag body 32 made of a breakable synthetic resin, and is arranged inside the tubular member 31, spanning the front connecting part 33 and the rear connecting part 34.

[0061] The front connecting part 33 is tapered to correspond to the tapered shape of the connecting pipe part 23 so that it can be inserted into the inside of the connecting pipe part 23 and tightly engage with it. The front connecting part 33 has a protrusion 35 on the outside that is inserted into and engages with the groove 25 of the connecting pipe part 23. The tip of the front connecting part 33 is provided with a sharp protrusion 37 that damages the storage bag body 32 when the storage bag body 32 is pushed forward. The rear connecting part 34 has a tapered shape that corresponds to the tapered shape of the nozzle 14 of the injector 10 so that it can fit onto the nozzle 14 of the injector 10. The outside of the rear connecting part 34 is provided with a groove 36 with which the protrusion 15 of the injector 10 can engage.

[0062] (Deodorant adjustment) In embodiment 1, povidone-iodine powder, an iodine-based deodorant, was used as deodorant 3. The povidone-iodine powder was produced as follows: 41.5 g of polyvinylpyrrolidone and 8.5 g of ground iodine were placed in a 300-milliliter beaker and stirred with a magnetic stirrer for half a day. The reaction product changed from light yellow to brown. It was then immersed in a 95°C oil bath and heat-treated for 24 hours. The resulting brown powder was a polyvinylpyrrolidone-iodine complex, i.e., povidone-iodine. The resulting povidone-iodine had an available iodine concentration of 12.2% according to sodium thiosulfate titration.

[0063] (Preparation of body fluid leakage prevention agent) The preparation of body fluid leakage prevention agent 2 will be described. 55.55 wt% ethylene glycol and 16 wt% polyethylene glycol were placed in an injection device equipped with a stirrer as solvents, and while stirring, 0.3 wt% carboxyvinyl polymer was added in small amounts and stirred for 2 to 8 hours. 26 wt% of a water-absorbent resin was then added to the resulting mucus base, followed by 0.1 wt% partially neutralized polyacrylic acid, and the mixture was thoroughly stirred. Subsequently, while stirring the mucus base in which the water-absorbent resin was dispersed, 2.05 wt% triethanolamine was added dropwise in small amounts, thereby preparing a body fluid leakage prevention agent with a pH of 7.0, designated Sample 1. The viscosity of Sample 1 was 119,300 cP.

[0064] The details of the body fluid leakage prevention agent are those disclosed in Japanese Patent Application Laid-Open No. 2002-275001, and a detailed description thereof will be omitted here.

[0065] (Example of a corpse treatment method using the corpse treatment device of embodiment 1) Next, we will explain an example of a method for treating a corpse using the corpse treatment device 1. This treatment method is an example in which a deodorant 3 and a bodily fluid leakage prevention agent 2 are injected into the throat B of the corpse S using an insertion tube 20 inserted into the nostril A.

[0066] First, the syringe 10 is removed from a film pack (not shown), and the cylindrical member 31 is removed from another film pack (not shown).

[0067] The front connecting portion 33 of the tubular member 31 is inserted into and fitted with the connecting tube portion 23 of the insertion tube 20, the protective cap 16 covering the nozzle 14 is removed, and the nozzle 14 is fitted into the rear connecting portion 34 of the tubular member 31, thereby connecting the insertion tube 20, the tubular member 31, and the injector 10 to each other.

[0068] Next, the tube main body 21 of the insertion tube 20 is inserted through the nostril A into the throat B, and the insertion is stopped when the stopper 24 of the insertion tube 20 comes into contact with the tip of the nose A1. Then, the piston 12 of the injector 10 is pressed to push the leakage prevention agent 2 in the syringe 11 into the tubular member 31. Then, the storage bag 32 moves toward the insertion tube 20, and the storage bag 32 is ruptured by the protrusion 37 provided on the front connecting part 33, causing the deodorant 3 to come out of the storage bag 32 and flow into the insertion tube 20 and into the throat B. At the same time, the leakage prevention agent 2 in the syringe 11 is injected into the throat B through the tubular member 31 and the insertion tube 20. After the deodorant 3 and the leakage prevention agent 2 have been injected into the throat B, the injector 10 and the tubular member 31 are pulled, and the insertion tube 20 is pulled out of the nostril A.

[0069] By this operation, the deodorant 3 and the agent for preventing leakage of bodily fluids 2 can be injected into the throat B of the corpse S through the same insertion tube 20.

[0070] As for the procedure, for example, the cylindrical member 31 and the syringe 10 may be connected first, and then the cylindrical member 31 and the insertion tube 20 may be connected. Alternatively, the insertion tube 20 may be inserted into the nostril A first, and then the deodorant-containing container 30 and the syringe 10 may be connected. In order to prevent the deodorant 3 in the cylindrical member 31 from leaking out when they are connected, it is preferable that the deodorant 3 be slightly viscous, such as in a jelly or gel state.

[0071] In the first embodiment, a deodorant-containing container 30 is used, but it is also possible to directly connect the insertion tube 20 and the syringe 10 without using the deodorant-containing container 30. When the syringe 10 and the insertion tube 20 are directly connected, the tapered surface of the nozzle 14 and the tapered surface of the connecting tube portion 23 come into close contact, and the protruding portion 15 of the nozzle 14 fits into the groove portion 25 of the connecting tube portion 23. With this type of connection, the body fluid leakage prevention agent 2 in the syringe 10 can be simply injected into the throat B via the insertion tube 20.

[0072] That is, by connecting the cylindrical member 31 between the injector 10 and the insertion tube 20, the deodorant 3 can be injected into the throat B via the insertion tube 20. Furthermore, if the corpse does not require injection of the deodorant 3, the cylindrical member 31 can be omitted.

[0073] In addition, in the first embodiment, the storage bag 32 of the tubular member 31 is pushed toward the insertion tube 20 by the bodily fluid leakage prevention agent 2, but the storage bag 32 may be pushed toward the insertion tube 20 by the nozzle 14. The storage bag 32 may be damaged by the tip of the nozzle 14. Alternatively, the storage bag 32 of the tubular member 31 may be damaged by another means, for example, by inserting a needle-like protrusion (not shown) into the opening of the front connecting portion 33 of the tubular member 31.

[0074] In the first embodiment, the deodorizer 3 is housed in a storage bag 32 and then housed in the tubular member 31, but it is also possible to house the deodorizer 3 directly in the tubular member 31 without housing it in the storage bag 32, and to cover the front and back with a cover or the like to prevent leakage.

[0075] In embodiment 1, the bodily fluid leakage prevention agent 2 is not mixed with the deodorant 3, but rather the bodily fluid leakage prevention agent 2 and the deodorant 3 are injected separately toward the throat B, so any type of deodorant 3 can be injected in any amount without interfering with the performance of the bodily fluid leakage prevention agent 2. Furthermore, because the bodily fluid leakage prevention agent 2 is injected into the throat B after the deodorant 3 has been injected, the bodily fluid leakage prevention agent 2 can prevent not only leakage of bodily fluids but also leakage of the deodorant 3 and odors.

[0076] Furthermore, since the deodorant 3 flows first and then the body fluid leakage prevention agent 2 flows within the same insertion tube 20, the flow of the deodorant 3 within the insertion tube 20 makes it easier for the body fluid leakage prevention agent 2 to flow within the insertion tube 20. The reason for this is not clear, but it is expected that the deodorant flows and causes less frictional resistance than within a dry tube.

[0077] (Foul-smelling compounds from corpses) A dead body contains various odor components such as ammonia, amines (isopropylamine), butyric acid (butanoic acid), hydrogen sulfide, and methyl mercaptan. Cadaverine (pentane-1,5-diamine) and putrescine may also be found in dead bodies.

[0078] In this invention, ammonia, isopropylamine, butanoic acid, hydrogen sulfide, and methyl mercaptan were selected as samples of malodorous compounds to test for deodorizing performance. Cadaverine and putrescine both have two amino groups (-NH2), and show the same tendency as isopropylamine, which has one amino group, so the experimental results can be easily predicted, so deodorizing tests for cadaverine and putrescine were omitted.

[0079] Ammonia gas was generated by heating aqueous ammonia (Wako Pure Chemical Industries, Ltd.) to 90°C. Amines were generated by heating isopropylamine (Tokyo Chemical Industry Co., Ltd.) to 90°C. Butanoic acid (butyric acid) was generated by heating Tokyo Chemical Industry Co., Ltd. to 90°C. Both were injected with a syringe to a gas concentration of 100 ppm and immediately sealed. Hydrogen sulfide was generated from aqueous ammonia sulfide (Wako Pure Chemical Industries, Ltd.) and hydrochloric acid (Wako Pure Chemical Industries, Ltd.). Methyl mercaptan (methanethiol) was obtained in an ampule as a benzene solution. After opening the ampule, the entire amount was collected with a syringe and placed in a petri dish in a Tedlar pack. The ampule was cooled, so methyl mercaptan was detected 10 minutes after the start of the experiment.

[0080] (Measuring equipment) The gas sampler used was GV-100S manufactured by Gastec Corporation, and a gas detector tube manufactured by Gastec Corporation was used.

[0081] (Deodorization test) 1 g of the povidone-iodine powder obtained as described above was spread as uniformly as possible in a 10 cm diameter petri dish. This was designated as deodorant A. Furthermore, a solution prepared by dissolving 1 g of the obtained povidone-iodine powder in 10 g of water was spread uniformly in a 10 cm diameter petri dish. This was designated as deodorant B.

[0082] The deodorants A and B prepared as described above were placed separately into 10-liter polyvinylidene fluoride resin tetra bags and sealed with tape, after which pure air was added using a pump-type air pump to bring the volume to 10 liters.

[0083] In this way, two types of tetra bags containing deodorizers A and B were prepared, one for each of the malodorous components: ammonia gas, isopropylamine, butanoic acid, hydrogen sulfide, and methyl mercaptan. A total of 10 types were prepared. Each malodorous component was separately injected into each of the tetra bags containing deodorizers A and B using a syringe so that the gas concentration became 100 ppm, and the lid was immediately closed.

[0084] For each tetra-bag prepared in this way, a gas detector tube was attached to the gas sampler and inserted into the tetra-bag for measurement at 0, 10, 30, 60, 120, 180, and 240 minutes. If the detected value was close to zero or if a trend could be predicted, further measurement was discontinued.

[0085] (Measurement results) Figures 3 to 7 are graphs showing the deodorizing performance when using the above-mentioned deodorizers A and B. Figure 3 shows the results of the deodorizing test for ammonia gas, Figure 4 for isopropylamine, Figure 5 for butanoic acid, Figure 6 for hydrogen sulfide, and Figure 7 for methyl mercaptan.

[0086] As shown in Figure 3, the povidone-iodine-based deodorant A was able to eliminate 60% of the ammonia odor after 30 minutes and 85% after 60 minutes, clearly demonstrating its deodorizing performance. In particular, when it was made into an aqueous solution of povidone-iodine, the odor was reduced to half after 10 minutes and 80% after 60 minutes, further improving the deodorizing performance.

[0087] As shown in Figure 4, the odor of isopropylamine was reduced by half after 60 minutes, and 85% was eliminated after 120 minutes, demonstrating its deodorizing performance. In particular, when it was mixed with an aqueous solution of povidone-iodine, the odor was reduced by half after 10 minutes, and 90% was eliminated after 60 minutes, further improving the deodorizing performance.

[0088] As shown in Figure 5, in the case of butanoic acid odor, the butanoic acid concentration dropped rapidly to below 10 percent in 10 minutes, demonstrating particularly remarkable deodorizing performance. Similar deodorizing performance was observed in the case of an aqueous solution of povidone-iodine.

[0089] As shown in Figure 6, the concentration of hydrogen sulfide odor was reduced by half after 30 minutes, and 80% was eliminated after 120 minutes, demonstrating the deodorizing performance. In particular, when it was used in an aqueous solution of povidone-iodine, 70% of the odor was eliminated after 30 minutes, and 0% after 120 minutes, demonstrating remarkable deodorizing performance.

[0090] As shown in Figure 7, the odor of methyl mercaptan was deodorized by 20% after 60 minutes, and reduced to half after 120 minutes, after which the deodorizing effect gradually increased. For reasons unknown, when povidone-iodine was dissolved in water, it exhibited a greater deodorizing effect than the powder in the 30-60 minute period, but after that the deodorizing effect gradually decreased, and after 100 minutes, povidone-iodine powder exhibited a greater deodorizing effect than the povidone-iodine aqueous solution.

[0091] As described above, povidone-iodine-based deodorants exhibit high deodorizing properties against various components of the odor of death, such as ammonia, amines (isopropylamine), butyric acid (butanoic acid), hydrogen sulfide, and methyl mercaptan.

[0092] From the above deodorization experiments, it is predicted that if the above deodorizer is injected into the body cavity of a corpse as a method of treating the corpse, the foul odor of the corpse can be eliminated, and that when the above deodorizer is used in the treatment device of embodiment 1, it will also be able to exhibit sufficient deodorizing performance.

[0093] That is, in the present invention, by placing a deodorant, an iodine-based deodorant, especially povidone-iodine, into the body cavity of a corpse, for example, the throat, various odors such as odors in body fluids and odors from internal organs that come out through the throat can be deodorized. Then, by sealing the cavity with a body fluid leakage prevention agent after the deodorant, leakage of the deodorant and odors can be prevented.

[0094] Furthermore, although no experiments have been conducted, iodine-based deodorants such as povidone iodine are said to have antibacterial and bactericidal effects against various viruses, and are thought to be effective in antibacterial and sterilizing corpses as well.

[0095] (Embodiment 2) A second embodiment of the present invention will be described with reference to Fig. 8. Only the parts that differ from the first embodiment will be described, and a description of the common parts will be omitted. The second embodiment differs from the first embodiment in that, while the first embodiment uses a cylindrical member 31 containing a deodorizer as the container 30 containing the deodorizer, the second embodiment uses an intermediate cylindrical body 41 that does not contain a deodorizer 3 and a stretchable bag 40 containing the deodorizer instead of the cylindrical member 31 containing the deodorizer.

[0096] The intermediate cylinder 41 has a front connecting part 42 connected to the insertion tube 20 and a rear connecting part 43 connected to the injector 10. The front connecting part 42 and the rear connecting part 43 of the intermediate cylinder 41 are similar to the front connecting part 33 and the rear connecting part 34 of the tubular member 31, and therefore a description thereof will be omitted. The intermediate cylinder 41 does not contain the deodorizer 3 in advance, but is connected to the insertion nozzle part 40a of the deodorizer-containing stretchable bag 40 so that the deodorizer 3 in the deodorizer-containing stretchable bag 40 can be introduced into the intermediate cylinder 41.

[0097] More specifically, a nozzle receiver 44 is provided between the front connecting portion 42 and the rear connecting portion 43 of the intermediate cylinder 41. The nozzle receiver 44 is provided on a reverse tapered wall portion 45 that connects the expanded diameter portion of the tapered front connecting portion 42 and the reduced diameter portion of the tapered rear connecting portion 43. The reverse tapered wall portion 45 is tapered in the opposite direction to the front connecting portion 42 and the rear connecting portion 43. A protruding cylinder portion 46 that protrudes diagonally outward toward the rear connecting portion 43 is provided on the side of the nozzle receiver 44. The inner surface of the protruding cylinder portion 46 is tapered and communicates with the interior of the nozzle receiver 44. When the insertion nozzle portion 40a of the deodorant-containing stretchable bag 40 is inserted into the protruding cylinder portion 46 of the nozzle receiver 44, the insertion nozzle portion 40a and the nozzle receiver 44 come into close contact with each other. When the insertion nozzle portion 40a of the deodorant-containing stretchable bag 40 is inserted into the nozzle receiver 44, the tip of the insertion nozzle portion 40a is exposed on the inner surface of the front connecting portion 42, but the exposed portion is the tapered wide portion on the inner surface of the front connecting portion 42, and there is almost no difference in the inner diameter of the tapered narrow portion on the inner surface of the rear connecting portion 43, so the tip of the insertion nozzle portion 40a does not hinder the passage of the bodily fluid leakage prevention agent 2.

[0098] The corpse treatment method of embodiment 2 will be described below.

[0099] By connecting the syringe 10 to the intermediate cylinder 41 and connecting the insertion tube 20 to the intermediate cylinder 41, the syringe 10, the intermediate cylinder 41, and the insertion tube 20 are connected in this order, and then the insertion tube 20 is inserted into the nostril A. When the stopper 24 of the insertion tube 20 reaches the tip of the nose A1, it is determined that the tip of the insertion tube 20 has reached the throat B, and the insertion of the insertion tube 20 into the nostril A is stopped. Thereafter, the insertion nozzle portion 40a of the stretchable bag 40 is inserted into the nozzle receiving portion 44 of the intermediate cylinder 41, and the stretchable bag 40 is contracted to push the deodorant 3 in the stretchable bag 40 into the intermediate cylinder 41. After the deodorant 3 has been sufficiently pushed out, the body fluid leakage prevention agent 2 from the syringe 10 is pushed into the intermediate cylinder 41. As a result, the deodorant 3 in the intermediate cylinder 41 is pushed by the bodily fluid leakage prevention agent 2 and passes through the insertion tube 20 first, and then the bodily fluid leakage prevention agent 2 passes through the insertion tube 20, and both are injected into the throat B. If it is necessary to prevent the bodily fluid leakage prevention agent 2 from flowing back into the stretchable bag 40, such as flowing into the stretchable bag 40, then after the deodorant 3 has been pushed out from the stretchable bag 40 into the intermediate cylinder 41, the passage of the insertion nozzle portion 40a may be blocked with, for example, a clip.

[0100] A lid (not shown) is attached to the insertion nozzle portion 40a of the stretchable bag 40 when not in use, and is removed when in use. Note that the stretchable bag 40 may be configured so that the lid breaks when the stretchable bag 40 is contracted without removing the lid attached to the insertion nozzle portion 40a of the stretchable bag 40. Alternatively, a needle-like pointed protrusion (not shown) may be used to make a hole in the lid and insert the lid into the nozzle receiver 44, or the nozzle receiver 44 may be provided with a protrusion (not shown) that breaks the lid when inserted into the nozzle receiver 44. Note that the insertion nozzle portion 40a of the stretchable bag 40 may not have a lid, and when a cap (not shown) is removed, a fine hole is opened at the tip so that the deodorant 3 can be dispensed when the stretchable bag 40 is pressed.

[0101] After connecting the syringe 10 to the intermediate cylinder 41 and connecting the insertion tube 20 to the intermediate cylinder 41, the insertion nozzle portion 40a of the stretchable bag 40 is inserted into the nozzle receiving portion 44 of the intermediate cylinder 41. However, the timing at which the insertion nozzle portion 40a of the stretchable bag 40 is inserted into the nozzle receiving portion 44 of the intermediate cylinder 41 and the timing at which the syringe 10 is connected to the intermediate cylinder 41 and the intermediate cylinder 41 is connected to the insertion tube 20 can be adjusted as desired during use and is not limited to the connection timing of embodiment 2.

[0102] In this embodiment 2, similar to embodiment 1, various odors of the corpse S can be deodorized, and leakage of the body fluids of the corpse S and the deodorant 3 is prevented by the body fluid leakage prevention agent 2. Furthermore, since the body fluid leakage prevention agent 2 passes after the deodorant 3 through the same insertion tube 20, the body fluid leakage prevention agent 2 passes easily and is smoothly injected into the throat B. Furthermore, in embodiment 2, by arbitrarily setting the capacity of the stretchable bag 40, the type and amount of deodorant 3 according to the corpse S can be injected.

[0103] Instead of the stretchable bag 40, a syringe similar to the syringe 10 may be connected to the nozzle receiver 44.

[0104] In the second embodiment, it has been explained that the intermediate cylinder 41 does not contain the deodorizer 3, but it is also possible to store the deodorizer 3 in the intermediate cylinder 41 in advance, connect the stretchable bag 40, and add more deodorizer 3 to the intermediate cylinder 41, and such a method is also included in the present invention.

[0105] (Embodiment 3) A third embodiment of the present invention will be described with reference to Fig. 9. Only the parts that differ from the first embodiment will be described, and a description of the common parts will be omitted. The third embodiment differs from the first embodiment in that, while the first embodiment used a deodorant-containing container 30 connected between the syringe 10 and the insertion tube 20, the third embodiment uses a deodorant-containing container 50 as a modified version of the deodorant-containing container 30. The deodorant-containing container 50 is attached to the tip of the insertion tube 20, rather than connecting the deodorant-containing container 30 between the syringe 10 and the insertion tube 20.

[0106] Specifically, as shown in FIG. 9, in the third embodiment, a breakable deodorant container 50 containing a deodorant is used. The deodorant container 50 has a long, tubular main body 51 and a tip portion 52 provided at the tip end. The tip portion 52 is provided with a thin portion 52a, making it easily breakable. This thin portion 52a can be easily broken with a needle-like protrusion or the like. The rear end side of the deodorant container 50 has an attachment portion 53 that can be externally fitted onto the nozzle 14 of the injector 10. The attachment portion 53 is designed to fit over the tip of the insertion tube 20 and fit tightly thereon.

[0107] The corpse treatment method of embodiment 3 will be described below.

[0108] During use, the thin-walled portion 52a of the tip 52 of the deodorant container 50 is broken by piercing it with a sharp object such as a needle, causing the deodorant 3 to flow out of the deodorant container 50. Since it is preferable that the deodorant 3 does not immediately flow out when the deodorant container 50 is broken, it is preferable that the deodorant 3 be made into a jelly-like substance with some viscosity. Alternatively, a jelly-like substance may be placed in the front of the deodorant container 50, and the deodorant 3 may be placed behind it. In such a double arrangement, the deodorant 3 may be in either liquid or powder form. Furthermore, when breaking the thin-walled portion 52a, instead of piercing it with a needle or the like, a needle-like protrusion (not shown) for breaking the thin-walled portion 52a may be detachably disposed at the tip of the insertion tube 20. When the bodily fluid leakage prevention agent 2 is extruded from the nozzle 14, the protrusion may fall off the nozzle 14 and be pushed into the deodorant container 50, thereby breaking the deodorant container 50. In this way, the deodorant container 50 is damaged when the bodily fluid leakage prevention agent 2 is pushed out of the insertion tube 20, eliminating the risk of the deodorant 3 leaking out from the deodorant container 50, and making it possible to use either liquid or powder deodorant 3. Also, the insertion tube 20 may be provided with a sharp protrusion so that the deodorant container 50 is damaged when inserted into the insertion tube 20.

[0109] In the third embodiment, the same effects as those of the first embodiment are achieved, and the existing injector 10 and insertion tube 20 can be used and simply connected, and the work is almost the same as the existing work, making the work easier for the worker.

[0110] (Embodiment 4) A fourth embodiment of the present invention will be described with reference to Fig. 10. Only the parts that differ from the third embodiment will be described, and a description of the common parts will be omitted. The fourth embodiment differs from the third embodiment in that, while the deodorant container 50 is attached to the tip of the insertion tube 20 in the third embodiment, the capsule 60 containing the deodorant is provided inside the injector 10, particularly near the nozzle 14 in the fourth embodiment.

[0111] The capsule 60 has an oval shape when viewed from the side, is made of a breakable or meltable material, and contains a deodorant 3 inside. The shell of the capsule 60 is made of a material that prevents the deodorant 3 inside from mixing with the bodily fluid leakage prevention agent 2 in the injector 10.

[0112] During use, the tip of the capsule 60 is pierced with a sharp object such as a needle to break it, causing the deodorant 3 inside the capsule 60 to spill out. Since it is preferable that the deodorant 3 does not immediately flow out when the capsule 60 is broken, it is preferable that the deodorant 3 be made, for example, jelly-like and have a slight viscosity. Alternatively, a jelly-like substance may be placed in the front of the capsule 60, and the deodorant 3 may be placed behind it. In such a double arrangement, the deodorant 3 may be in either liquid or powder form. Instead of piercing the capsule 60 with a needle or the like to break it, a needle-like protrusion for breaking it (not shown) may be disposed at the tip of the nozzle 14 so that it can fall off. When the bodily fluid leakage prevention agent 2 is extruded from the nozzle 14, the needle-like protrusion for breaking it may fall off the nozzle 14 and be pushed into the capsule 60, thereby breaking the capsule 60. In this way, after the insertion tube 20 and the injector 10 are connected, the capsule 60 is broken when the capsule 60 moves, so there is no risk of the deodorant 3 in the capsule leaking out, and the deodorant 3 can be applied whether it is liquid or powder.

[0113] Furthermore, the capsule 60 does not have to be breakable, and for example, the shell may be made of a dissolvable material so that it can be passed through the insertion tube 20 together with the body fluid leakage prevention agent 2 and inserted into the nostril A. In this case, the capsule 60 is preferably made of a flexible material like the insertion tube 20 so that the capsule 60 does not create resistance in the insertion tube 20 and the nostril A. In this case, the capsule 60 is designed to dissolve when injected into the throat B.

[0114] In the fourth embodiment, the same effects as those of the first embodiment are achieved, and the existing injector 10 and insertion tube 20 can be used and simply connected, and the work is the same as the existing work, making the work easier for the worker.

[0115] (Embodiment 5) A fifth embodiment of the present invention will be described with reference to FIG. 11. Only the differences from the fourth embodiment will be described, and a description of the common parts will be omitted. The fifth embodiment differs from the fourth embodiment in that, while the capsule 60 is disposed near the nozzle 14 of the injector 10 in the fourth embodiment, the capsule 60 is provided inside the insertion tube 20 in the fifth embodiment. The capsule 60, like the insertion tube 20, is made of a flexible material so that it does not provide resistance when the insertion tube 20 is inserted into the nostril A. The deodorant 3 may be in the form of a liquid, powder, or jelly.

[0116] Although the capsule 60 is placed at the tip of the insertion tube 20, it does not necessarily have to be at the tip and may be placed at any position. However, placing the capsule 60 at the tip of the insertion tube 20 prevents the capsule 60 from moving a long distance inside the insertion tube 20, allowing the capsule 60 and the bodily fluid leakage prevention agent 2 to pass through the insertion tube 20 easily.

[0117] In the fifth embodiment, the same effects as those of the first embodiment are achieved, and the existing injector 10 and insertion tube 20 can be used and simply connected, and the work is almost the same as the existing work, making the work easier for the operator.

[0118] (Embodiment 6) A sixth embodiment of the present invention will be described with reference to FIG. 12. Only the differences from the first embodiment will be described, and a description of the common parts will be omitted. The sixth embodiment differs from the first embodiment in that, while the first embodiment provided a deodorant-containing container 30 between the syringe 10 and the insertion tube 20, the sixth embodiment stores the body fluid leakage prevention agent 2 in the first syringe 10a and the deodorant 3 in the second syringe 10b, and the first syringe 10a and the second syringe 10b are alternately connected to the insertion tube 20. That is, in the sixth embodiment, the first syringe 10a containing the body fluid leakage prevention agent 2 and the second syringe 10b containing the deodorant 3 are prepared, and the first syringe 10a and the second syringe 10b are reconnected to the same insertion tube 20.

[0119] First syringe 10a is similar to syringe 10 of embodiment 1, and therefore a description thereof will be omitted. Second syringe 10b is connectable to insertion tube 20 in the same way as first syringe 10a, but differs in that it contains deodorant 3 instead of bodily fluid leakage prevention agent 2 and has a smaller capacity. Second syringe 10b includes syringe 11a, piston 12a, cylindrical container 13a, nozzle 14a, protrusion 15a, and cap 16a, which are similar to syringe 11, piston 12, cylindrical container 13, nozzle 14, protrusion 15, and cap 16 of first syringe 10a.

[0120] During use, in the sixth embodiment, the insertion tube 20 connected to the second injector 10b is inserted into the nostril A, and the deodorant 3 in the second injector 10b is injected into the throat B via the insertion tube 20. Thereafter, the second injector 10b is removed from the insertion tube 20, and the first injector 10a containing the body fluid leakage prevention agent 2 is connected to the insertion tube 20. Then, the body fluid leakage prevention agent 2 is injected into the throat B via the insertion tube 20. Through these operations, the deodorant 3 and the body fluid leakage prevention agent 2 can be injected into the throat B. Thereafter, the insertion tube 20 is pulled out from the nostril A with the first injector 10a still connected.

[0121] In the sixth embodiment, although it is time-consuming to switch between the second injector 10b containing the deodorant 3 and the first injector 10a containing the body fluid leakage prevention agent 2, it is possible to inject the type of deodorant 3 and the required amount of deodorant 3 according to the condition of the corpse S into the throat B.

[0122] The deodorant 3 may be in liquid or powder form, or may be in a jelly form like the body fluid leakage prevention agent 2. If the deodorant 3 is in a jelly form, the deodorant 3 is less likely to leak from the insertion tube 20 or the second syringe 10b even when the second syringe 10b is pulled out of the insertion tube 20 when replacing the second syringe 10b with the first syringe 10a.

[0123] If the amount of deodorant 3 can be smaller than the amount of body fluid leakage prevention agent 2, second injector 10b may be a small injector.

[0124] The second injector 10b is similar to the first injector 10a, but is not limited to this second injector 10b. For example, the second injector 10b may be bag-shaped like the deodorizer-containing stretchable bag 40 of embodiment 2 and connected to the insertion tube 20.

[0125] In the sixth embodiment, the same effects as those of the first embodiment are achieved, and since the existing injector 10 and insertion tube 20 can be used, the existing injector 10 and insertion tube 20 are not wasted.

[0126] Furthermore, in the case of a body into which deodorant 3 is not to be injected, the second injector 10b is not connected to the insertion tube 20, and the injector 10 can be connected to the insertion tube 20 as before and used, so the equipment can be used both when deodorant 3 is used and when it is not, eliminating waste.

[0127] (Embodiment 7) A seventh embodiment of the present invention will be described with reference to Figure 13. Only the parts that differ from the sixth embodiment will be described, and a description of the common parts will be omitted. The seventh embodiment differs from the sixth embodiment in that, whereas in the sixth embodiment, the second syringe 10b containing the deodorant 3 and the first syringe 10a containing the body fluid leakage prevention agent 2 were interchangeably connected to the insertion tube 20, in the seventh embodiment, the shape of the insertion tube 20 has been devised so that the second syringe 10b containing the deodorant 3 and the first syringe 10a containing the body fluid leakage prevention agent 2 do not need to be interchanged.

[0128] Specifically, in the seventh embodiment, a bifurcated insertion tube 80 is used as the insertion tube 20, as shown in FIG. 13, instead of the insertion tube 20 shown in the sixth embodiment.

[0129] The pipe main body 81 and injection hole 82 of the bifurcated insertion pipe 80 of embodiment 7 are similar to the pipe main body 21 and injection hole 22 of the insertion pipe 20 of embodiment 6, and detailed description thereof will be omitted. The bifurcated insertion pipe 80 differs from the insertion pipe 20 in that the connecting pipe 83 includes a first connecting pipe portion 83a and a second connecting pipe portion 83b. A first injector 10a containing a body fluid leakage prevention agent 2 is connected to the first connecting pipe portion 83a, and a second injector 10b containing a deodorant 3 is connected to the second connecting pipe portion 83b. Both the first injector 10a and the second injector 10b of embodiment 7 are similar to the first injector 10a and the second injector 10b of embodiment 6, and detailed description thereof will be omitted.

[0130] In use, in the seventh embodiment, for example, first syringe 10a is connected to first connecting pipe portion 83a, and second syringe 10b is connected to second connecting pipe portion 83b, and then tube body portion 81 of bifurcated insertion tube 80 is inserted into nostril A. After insertion, deodorant 3 in second syringe 10b is passed through second connecting pipe portion 83b and tube body portion 81 of bifurcated insertion tube 80 and introduced into throat B, and then bodily fluid leakage prevention agent 2 in first syringe 10a is passed through first connecting pipe portion 83a and tube body portion 81 of bifurcated insertion tube 80 and introduced into throat B. By this procedure, deodorant 3 can be injected into throat B first, and then bodily fluid leakage prevention agent 2 can be injected into throat B. This can eliminate various components of the corpse odor and prevent the corpse odor and bodily fluids from leaking from the throat.

[0131] In the above embodiment, the first injector 10a and the second injector 10b are connected to the bifurcated insertion tube 80 before inserting the bifurcated insertion tube 80 into the nostril A. However, it is also possible to connect only one of the injectors and then insert it into the nostril A, and then connect the other to the bifurcated insertion tube 80. Alternatively, the bifurcated insertion tube 80 may be inserted into the nostril A first, and then the first injector 10a and the second injector 10b may be connected to the bifurcated insertion tube 80, respectively.

[0132] In the seventh embodiment, the same effects as those of the first embodiment are achieved, and by using the bifurcated insertion tube 80 as the insertion tube, there is no need to insert and remove the first injector 10a and the second injector 10b to switch between them when injecting the body fluid leakage prevention agent 2 and the deodorant 3, which improves workability. Furthermore, the tube body 81 of the bifurcated insertion tube 80 is the same as the tube body 21 of the insertion tube 20, and can be inserted into the nostril A in the same manner as before, allowing the operator to work without any discomfort.

[0133] In the seventh embodiment, the deodorant 3 first passes through the pipe body 81 of the bifurcated insertion pipe 80, and then the bodily fluid leakage prevention agent 2 passes through, so that the bodily fluid leakage prevention agent 2 can easily pass through the pipe body 81.

[0134] (Embodiment 8) An eighth embodiment of the present invention will be described with reference to Figure 14. Only the differences from the seventh embodiment will be described, and a description of the common parts will be omitted. The eighth embodiment differs from the seventh embodiment in that, while the seventh embodiment uses a bifurcated insertion tube 80 connectable to the first injector 10a and the second injector 10b, the eighth embodiment uses two types of insertion tubes 90 instead of the bifurcated insertion tube 80. Specifically, a first insertion tube 91 is used to pass the body fluid leakage prevention agent 2, and a second insertion tube 92 is provided to pass the deodorant 3, and the first insertion tube 91 and the second insertion tube 92 are inserted into the nostril A separately.

[0135] The first insertion tube 91 differs from the tube body 21 of embodiment 7 in that the tube body 91a is curved at the tip, but is basically configured similarly to the tube body 21 of the insertion tube 20 of embodiment 2, and therefore a description thereof will be omitted. An injection hole 91b is provided at the tip of the tube body 91a. The second insertion tube 92 has a smaller diameter than the first insertion tube 91 and, like the first insertion tube 91, is made of a tube made of a flexible synthetic resin material such as soft polyvinyl chloride, and has an injection hole 92b at its tip. The tube body 92a of the second insertion tube 92 is curved to correspond to the shape of the tube body 91a of the first insertion tube 91.

[0136] During use, the first syringe 10a is connected to the first insertion tube 91, and the second syringe 10b is connected to the second insertion tube 92. Then, the second insertion tube 92 is inserted into the nostril A, and the deodorant 3 is injected into the throat B through the second insertion tube 92. Thereafter, the second syringe 10b is pulled to remove the second insertion tube 92 from the nostril A. Then, the first insertion tube 91, to which the first syringe 10a is connected and which contains the body fluid leakage prevention agent 2, is inserted into the nostril A from which the second insertion tube 92 has been removed. At this time, the nostril A is the nostril A through which the small-diameter second insertion tube 92 has been passed once, and the first insertion tube 91, which has a slightly larger diameter than the second insertion tube 92, can be easily inserted into the nostril A. Then, the body fluid leakage prevention agent 2 is injected into the throat B through the first insertion tube 91. After injection, the first insertion tube 91 is pulled out from the nostril A. By first passing the small-diameter second insertion tube 92 through the same nostril A and then passing the large-diameter second insertion tube 92 thereafter, the small-diameter second insertion tube 92 enlarges the passage to some extent relative to the nostril A, making it easier to pass the large-diameter second insertion tube 92 through.

[0137] In the eighth embodiment, the first insertion tube 91 and the second insertion tube 92 are inserted into the same nostril A, but it is also possible to insert the first insertion tube 91 and the second insertion tube 92 into different nostrils A. In this case, it is not necessary to alternately remove and insert the first insertion tube 91 and the second insertion tube 92.

[0138] In embodiment 8, the same effect as embodiment 1 is achieved, and a first insertion tube 91 for passing the body fluid leakage prevention agent 2 and a second insertion tube 92 for passing the deodorant 3 are provided, so that the required type of deodorant can be injected in the required amount, and there is absolutely no risk of the deodorant leaking.

[0139] (Embodiment 9) A ninth embodiment of the present invention will be described with reference to Fig. 15. Only the differences from the eighth embodiment will be described, and a description of the common parts will be omitted. The ninth embodiment differs from the eighth embodiment in that the first and second insertion tubes 91 and 92 of the insertion tube 90 are separate bodies in the eighth embodiment, whereas the first and second insertion tubes 91 and 92, which have a smaller diameter than the first insertion tube 91, are integrated into one body in the ninth embodiment.

[0140] The second insertion tube 92 is attached to the outer periphery of the first insertion tube 91, and the first insertion tube 91 and the second insertion tube 92 are inserted together into the nostril A. Similar to the second embodiment, the deodorant-containing stretchable bag 40 is connected to the second insertion tube 92 instead of the second syringe 10b. Although the first syringe 10a is omitted in FIG. 15, the first syringe 10a is connected to the first insertion tube 91, and the body fluid leakage prevention agent 2 is injected.

[0141] In use, the first syringe 10a is connected to the first insertion tube 91, and the first insertion tube 91 and the second insertion tube 92 are inserted together into the nostril A. After insertion, the deodorant-containing stretchable bag 40 is contracted, and the deodorant 3 in the stretchable bag 40 is introduced into the throat B via the second insertion tube 92, and then the bodily fluid leakage prevention agent 2 in the first syringe 10a is introduced into the throat B through the first insertion tube 91.

[0142] In the ninth embodiment, the same effects as those of the first embodiment are achieved, and a first insertion tube 91 for passing the body fluid leakage prevention agent 2 and a second insertion tube 92 for passing the deodorant 3 are provided, so there is no need to switch between the insertion tube 20 and the injector 10, and the required type of deodorant can be injected in the required amount, without any risk of the deodorant leaking.

[0143] Furthermore, in the ninth embodiment, a stretchable bag 40 containing a deodorizer is used, but this is not limited to the stretchable bag 40 containing a deodorizer, and any other container containing a deodorizer may be used, for example, the second injector 10b as in the eighth embodiment may be used.

[0144] In FIG. 15, the second insertion tube 92 is positioned so as to overlap the injection holes 91b of the first insertion tube 91, but it may be provided so as to pass between the injection holes 91b.

[0145] In addition, the second insertion tube 92 provided on the outer periphery of the first insertion tube 91 is provided on the upper surface side in FIG. 15, but this is not limited to this position and it may be provided on the lower surface side or side surface side.

[0146] In addition, in the ninth embodiment, the second insertion tube 92 is provided on the outer periphery of the first insertion tube 91, but the second insertion tube 92 may be provided inside the first insertion tube 91. In this way, the existing insertion tube can be inserted into the nostril A without changing the diameter of the existing insertion tube.

[0147] Although the first to ninth embodiments are examples in which the insertion tube 20 or the insertion tube 90 is inserted into the nostril A, it is also possible to insert the insertion tube 20 or the insertion tube 90 into the oral cavity G and inject the deodorant 3 and the body fluid leakage prevention agent 2 into the throat B, and such a method is also included in the present invention.

[0148] (Embodiment 10) A tenth embodiment of the present invention will be described with reference to FIG. 16. Only differences from the ninth embodiment will be described, and commonalities will be omitted. The tenth embodiment differs from the ninth embodiment in that, while the ninth embodiment uses a first insertion tube 91 containing a body fluid leakage prevention agent 2 and a second insertion tube 92 containing a deodorant 3 as the insertion tube 20, the tenth embodiment uses the first insertion tube 91 and the first injector 10a but does not use a deodorant-containing elastic bag 40 or the second insertion tube 92, thereby simplifying the procedure. Specifically, a deodorant-containing capsule 60 or a tablet-shaped deodorant (hereinafter referred to as a tablet) 70 is prepared, and the capsule 60 or tablet 70 is inserted into the throat B through the nostril A or the oral cavity G. FIG. 16(a) shows a soft capsule 60, and FIG. 16(b) shows a tablet 70. As examples of the soft capsule 60, an oval-shaped type and a suppository-shaped type have been described. The shape of the capsule 60 is not limited to these and may be other shapes. Also, a cylindrical shape has been described as an example of the tablet 70. The shape of the tablet 70 is not limited to these and may be other shapes.

[0149] As a means for inserting the capsule 60 or the tablet 70 into the throat B, for example, the oral cavity G is opened wide using an oral airway (not shown) that is inserted from the oral cavity, and the capsule 60 or the tablet 70 is held with the operator's hand or a tool (not shown) and inserted into the throat B. Alternatively, a method of attaching the capsule 60 or the tablet 70 to the tip of an oral airway and inserting it from the oral cavity G into the throat B can be used.

[0150] It is also possible to use microcapsules instead of capsules 60. In the present invention, microcapsules are povidone-iodine fine powders individually wrapped in a film-forming material. The film-forming material may be, for example, water-soluble and alcohol-resistant, and may cover the outer periphery of the povidone-iodine powder and hold it in the jelly. For example, sodium carboxymethylcellulose, carboxyl cellulose, methyl cellulose, and morpholine fatty acid salts are effective film-forming materials. The film-forming material preferably has a thickness of 0.01 μm or more and 3.00 μm or less.

[0151] It has been found that if povidone-iodine powder is mixed into the jelly of the body fluid leakage prevention agent 2, it reacts with the ingredients in the jelly, impairing the deodorizing function, so povidone-iodine powder cannot be dispersed and mixed into the jelly as is. However, as mentioned above, if microcapsules are used, the fine povidone-iodine powder can be encapsulated in a film-forming material, allowing it to be mixed into the jelly of the body fluid leakage prevention agent 2.

[0152] It is not clear which component in the jelly of Body Fluid Leakage Prevention Agent 2 the povidone-iodine powder reacts with, causing the deodorizing function to deteriorate, but it is predicted that it will react with either carboxyvinyl polymer, partially neutralized polyacrylic acid, or triethanolamine.

[0153] In the above embodiment, an example was described in which the deodorant 3 and the body fluid leakage prevention agent 2 were injected into the throat B, but the application is not limited to the throat B and can also be applied to other body cavities, such as the anus, the female vagina, ears, wounds, bedsores, stomas, etc. [Industrial Applicability]

[0154] The present invention can be used as a method for treating a corpse by injecting a body fluid leakage prevention agent and a deodorant into body cavities such as the throat and anus of the corpse using a body treatment device (loader) containing the body fluid leakage prevention agent. [Explanation of symbols]

[0155] 1. Corpse handling equipment 2. Leak prevention agent 3. Deodorant 10 syringe 10a 1st syringe 10b 2nd syringe 20 Insertion tube 30 deodorant containers 31 Cylindrical member 33 Front connection part 34 Rear connection part 40 Deodorizer-filled stretchable bag (container) 40a Insertion nozzle part 41 Intermediate cylinder (container) 42 Front connection part 43 Rear connection part 50 Deodorant container (container) 60 capsules 70 tablets 80 Forked Insertion Tube 81 Pipe body 82 Injection hole 83a First connecting pipe section 83b Second connecting pipe section 90 Insertion tube 91 First Intubation Tube 91a Pipe body 91b Injection hole 92 Second Intubation Tube 92a Tube body 92b Injection hole S Corpse A nostril B. Throat G Oral

Claims

1. providing a syringe containing a leakage prevention agent; A method for treating a corpse, comprising extruding the agent for preventing leakage of body fluids from a body cavity of the corpse by injecting the agent for preventing leakage of body fluids from the body cavity, A method for treating a corpse, characterized in that a deodorant containing povidone iodine is injected into the body cavity before the agent for preventing leakage of body fluids is injected into the body cavity.

2. The method for treating a corpse according to claim 1, preparing an insertion tube to be inserted into the nostrils or oral cavity of the corpse and to guide the bodily fluid leakage prevention agent in the syringe to the throat of the corpse; A method for treating a corpse, characterized in that the deodorant is injected into the throat of the corpse before the bodily fluid leakage prevention agent in the syringe is injected into the throat of the corpse through the insertion tube.

3. The method for treating a corpse according to claim 2, A method for treating a corpse, characterized in that the bodily fluid leakage prevention agent is a jelly-like bodily fluid leakage prevention agent consisting of a jelly whose main component is alcohol-based and in which a large number of highly absorbent polymer powders are dispersed.

4. The method for treating a corpse according to claim 2 or 3, A method for treating a corpse, characterized in that the deodorant is injected toward the throat through the insertion tube inserted into the nostril or oral cavity.

5. The method for treating a corpse according to claim 4, Prepare a container of deodorant, A method for treating a corpse, characterized in that the deodorizer in the container containing the deodorizer is poured into the insertion tube, and then the body fluid leakage prevention agent is poured into the insertion tube and injected into the throat.

6. The method for treating a corpse according to claim 5, After connecting the container containing the deodorant to the insertion tube, the insertion tube is inserted into the nostril or the oral cavity, and the deodorant is injected into the throat region through the insertion tube; Next, after removing the container containing the deodorant from the insertion tube, the syringe containing the bodily fluid leakage prevention agent is connected to the insertion tube, and then the bodily fluid leakage prevention agent is injected into the throat through the insertion tube.

7. The method for treating a corpse according to claim 5, the insertion pipe is a bifurcated insertion pipe including a first connecting pipe portion to which the injector can be connected and a second connecting pipe portion to which the deodorant-containing container can be connected, A method for treating a corpse, comprising the steps of: connecting the syringe and the container containing the deodorant to the first connecting tube portion and the second connecting tube portion of the bifurcated insertion tube, respectively; inserting the bifurcated insertion tube into the nostrils and the oral cavity; and then first injecting the deodorant from the container toward the throat through the bifurcated insertion tube; and then injecting the bodily fluid leakage prevention agent from the syringe toward the throat through the bifurcated insertion tube.

8. The method for treating a corpse according to claim 5, the insertion pipe is a bifurcated insertion pipe including a first connecting pipe portion to which the injector can be connected and a second connecting pipe portion to which the deodorant-containing container can be connected, After inserting the bifurcated insertion tube into the nostril or the oral cavity, connect the syringe containing the body fluid leakage prevention agent to a first connecting tube part of the bifurcated insertion tube and the container containing the deodorant to a second connecting tube part of the insertion tube, Thereafter, the deodorant in the container is first injected toward the throat through the bifurcated insertion tube, and then the bodily fluid leakage prevention agent in the syringe is injected toward the throat through the insertion tube.

9. The method for treating a corpse according to claim 5, the deodorant-containing container comprises a tubular member having a front connecting part connectable to the insertion tube at its front side and a rear connecting part connectable to the injector at its rear side; the front connecting portion of the tubular member is connected to the insertion tube and the rear connecting portion is connected to the injector, and then the insertion tube is inserted into the nostril or the oral cavity; Then, the bodily fluid leakage prevention agent in the injector is pushed toward the tubular member via the rear connecting portion, and the deodorant in the tubular member is pushed into the insertion tube via the front connecting portion, and the bodily fluid leakage prevention agent is pushed into the insertion tube following the deodorant, and these are sequentially injected into the throat.

10. The method for treating a corpse according to claim 5, an intermediate cylinder having a front connecting portion connectable to the insertion tube at its front end, a rear connecting portion connectable to the injector at its rear end, and an insertion port at its midpoint into which the deodorant-containing container can be inserted; connecting the front connecting portion of the intermediate cylinder to the insertion tube and the rear connecting portion to the injector, and then inserting the insertion tube into the nostril or the oral cavity; Then, insert the container containing the deodorant into the insertion port of the intermediate cylinder, and pour the deodorant into the intermediate cylinder; A method for treating a corpse, characterized in that the bodily fluid leakage prevention agent in the injector is pushed toward the intermediate cylinder through the rear connecting portion, the deodorant in the intermediate cylinder is pushed out into the insertion tube through the front connecting portion, and the bodily fluid leakage prevention agent is pushed out into the insertion tube following the deodorant, and these are sequentially injected into the throat.

11. The method for treating a corpse according to claim 5, the deodorant container is meltable or breakable within the injector; A method for treating a corpse, characterized in that after the container containing the deodorant is melted or broken, the bodily fluid leakage prevention agent in the syringe is pushed out toward the insertion tube, and the deodorant in the container containing the deodorant is also pushed out.

12. The method for treating a corpse according to claim 5, the deodorant container is attached to the distal end of the insertion tube in a meltable or breakable manner; A method for treating a corpse, characterized in that the deodorant-containing container is pushed into the throat while still containing the deodorant by a bodily fluid leakage prevention agent that is pushed from the inside of the injector through the insertion tube toward the throat, and then the deodorant-containing container is melted or broken in the throat.

13. The method for treating a corpse according to claim 5, the deodorant container is breakably disposed within the insertion tube; A method for treating a corpse, characterized in that the bodily fluid leakage prevention agent in the syringe is sent to the insertion tube to break the deodorant container, thereby forcing the deodorant from the insertion tube to the throat, and then the bodily fluid leakage prevention agent is also forked toward the throat.

14. The method for treating a corpse according to claim 4, the insertion tube includes a first insertion tube through which the body fluid leakage prevention agent passes and a second insertion tube through which the deodorant passes; After inserting the second insertion tube into the nostril or the oral cavity, the deodorant is injected into the throat region through the second insertion tube; Then, the first insertion tube is inserted into the nostril or oral cavity, and the bodily fluid leakage prevention agent is injected into the throat through the first insertion tube.

15. The method for treating a corpse according to claim 14, A method for treating a corpse, wherein the outer diameter of the second insertion tube is smaller than the outer diameter of the first insertion tube.

16. The method for treating a corpse according to claim 4, the insertion tube includes a first insertion tube through which the body fluid leakage prevention agent passes and a second insertion tube through which the deodorant passes; A method for treating a corpse, characterized in that the second insertion tube is formed integrally with the first insertion tube and is inserted into the nostril or oral cavity together with the first insertion tube.

17. The method for treating a corpse according to claim 14 or 15, A method for treating a corpse, characterized in that the second insertion tube is provided separately from the first insertion tube and is inserted into the nostril or oral cavity separately from the first insertion tube.

18. The method for treating a corpse according to any one of claims 1 to 3, The deodorant is comprised of a capsule contained in a meltable envelope or a tablet made by compacting powder into a predetermined size, inserting the capsule or the tablet into the body cavity of the corpse; A method for treating a corpse, characterized in that the body fluid leakage prevention agent in the injector is then injected into the body cavity.

Images